The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
GoldmanI.D., ZhaoR.Molecular, biochemical, and cellular pharmacology of pemetrexed. Sem Oncol.2002; 29(6 suppl 18):3–17.
3.
Paz-AresL., BezaresS., TaberneroJ.M.Review of a promising new agent: pemetrexed disodium. Cancer.2003; 97(8 suppl):2056–63.
4.
GarnickM.B., CampionM., KucaB.PSA kinetics: Rates of decline are significantly more rapid following therapy with the GnRH antagonist Abarelix-Depot (AD), compared to superagonists Lupron (L) and Zoladex (Z) in prostate cancer (PrCa) patients [abstract]. J Urol.1999; 161(4 suppl):98.
5.
GarnickM.B., TomeraK., CampionM.Abarelix-Depot (A-D), a sustained-release (SR) formulation of a potent GNRH pure antagonist in patients with prostate cancer (PrCa): Phase II clinical results and endocrine comparison with superagonists Lupron (L) and Zoladex (Z) [abstract]. J Urol.1999; 161(4 suppl):340.
6.
GarnickM.B., CampionM.Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol.2000; 4(3): 275–7.
7.
TomeraK., GleasonD., GittelmanM., for the Abarelix Study Group. The gonadotropin-releasing hormone antagonist Abarelix Depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol.2001; 165(5): 1585–9.
8.
McLeodD., ZinnerN., TomeraK., for the Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology.2001; 58(5): 756–61.
9.
TrachtenbergJ., GittlemanM., SteidleC., for the Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol.2002; 167(4): 1670–4.
10.
BeerT.M., GarzottoM., EilersK.M.Phase II study of Abarelix Depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol.2003; 169(5): 1738–41.
11.
KochM., SteidleC., BrosmanS., for the Abarelix Study Group. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology.2003; 62(5): 877–82.
12.
MarthaP.M., GrayM.E., CampionM.Abarelix-Depot, a potent pure GnRH antagonist, rapidly induced sustained suppression of the pituitarygonadal axis in women with endometriosis. Fertility Sterility.1999; 71(4 suppl):9S.
HughesA., CalvertP., AzzabiA.Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol.2002; 20(16): 3533–44.
15.
VogelzangN., PaolettiP., SymanowskiJ.Pemetrexed plus cisplatin vs cisplatin alone in chemonaive patients with malignant pleural mesothelioma: Results of a phase III trial. Ann Oncol.2002; 13(suppl 1): 129.
16.
ScagliottiG.V., ShinD.M., KindlerH.L.Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol.2003; 21(8): 1556–61.
17.
VogelzangN.J., RusthovenJ.J., SymanowskiJ.Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol.2003; 21(14): 2636–44.
18.
ManegoldC., GatzemeierU., von PawelJ.Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol.2000; 11(4): 435–40.
19.
ShepherdF.A., DanceyJ., ArnoldA.Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer.2001; 92(3): 595–600.
20.
ClarkeS., UnderhillC., WhiteS.Phase II study of pemetrexed and vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol.2002; 13(suppl 1): 149.
21.
SmitE.F., MattsonK., von PawelJ.ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol.2003; 14(3): 455–60.
22.
MonneratC., Le ChevalierT., NovelloS.Clinical results from a phase II trial of pemetrexed plus gemcitabine in advanced non-small cell lung cancer. Ann Oncol.2002; 13(suppl 1): 132.
23.
RusthovenJ.J., EisenhauerE., ButtsC.Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.1999; 17(4): 1194–9.
24.
ClarkeS.J., AbrattR., GoedhalsL.Phase II trial of pemetrexed disodium (ALIMTA), LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol.2002; 13(5): 737–41.
25.
CelioL., BajettaE., FerrariL.The multi-targeted antifolate pemetrexed disodium (Alimta) with folic acid (FA) supplementation in advanced gastric cancer. Ann Oncol.2001; 12(suppl 1): 85.
26.
BajettaE., CelioL., BuzzoniR.Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol.2003; 14(10): 1543–8.
27.
CrippsC., BurnellM., JolivetJ.Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol.1999; 10(10): 1175–9.
28.
JohnW., PicusJ., BlankeC.D.Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study. Cancer.2000; 88(8): 1807–13.
29.
MillerK.D., PicusJ., BlankeC.Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol.2000; 11(1): 101–3.
30.
MartinM., SpielmannM., NamerM.Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol.2003; 14(8): 1246–52.
31.
MilesD.W., SmithI.E., ColemanR.E.A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer.2001; 37(11): 1366–71.
32.
PivotX., RaymondE., LaguerreB.Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer.2001; 85(5): 649–55.
